ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Periostin-CCL3 Feedforward Signaling Loop Promotes Cardiac Fibrosis and Cardiomyocyte Necroptosis in Arrhythmogenic Cardiomyopathy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Periostin (POSTN) is a multifunctional extracellular matrix protein in cardiovascular diseases. However, its role in arrhythmogenic cardiomyopathy (ACM) remains unknown. Here, we demonstrate that POSTN is significantly elevated in the myocardium of ACM mice and patients. POSTN deficiency alleviates heart dysfunction, reduces cardiac fibrosis and improves survival rates in ACM mice. POSTN is mainly derived from cardiac myofibroblasts and promotes cardiomyocyte necroptosis in vivo and in vitro. Mechanistically, POSTN facilitates cardiomyocyte necroptosis through the integrin-JNK-RIP3-MLKL signaling and induces CCL3 expression via the integrin-JNK-ETS2 pathway. In turn, CCL3 activates cardiac myofibroblasts and stimulates POSTN expression through the NF-κB signaling. Our findings show that POSTN and CCL3 facilitate ACM progression through the POSTN-integrin-JNK-ETS2-CCL3 signaling in cardiomyocytes and CCL3-CCR5-NF-κB-POSTN axis in cardiac myofibroblasts. We further found that pharmacological inhibition of either JNK or CCR5 to target JNK-CCL3-CCR5 axis attenuates subsequent ACM progression in mice by suppressing cardiac fibrosis and cardiomyocyte necroptosis. Therefore, targeting the POSTN-CCL3 feedforward signaling loop may offer a novel therapeutic strategy for patients with ACM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.